Several clinical trials support the use of peroxisome proliferator-activated receptor (PPAR) agonists to treat dyslipidemia and insulin resistance in obesity and type 2 diabetes. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.